- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05309421
Un ensayo de un solo brazo que evalúa la eficacia y la seguridad de EVX-01 en combinación con pembrolizumab en adultos con melanoma irresecable o metastásico
Un ensayo abierto de un solo brazo que evalúa la eficacia y la seguridad de EVX-01 en combinación con pembrolizumab en adultos sin tratamiento previo con inhibidores de puntos de control con melanoma no resecable o metastásico
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Patients will initiate treatment with pembrolizumab at the start of the trial and receive up to 18 treatment cycles (approximately 2 years). Immunization with the EVX-01 will be initiated at Week 12. In total, 10 doses of EVX-01 will be administered intramuscularly, with 6 doses given two weeks apart and 4 booster doses at later time points.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New South Wales
-
Wollstonecraft, New South Wales, Australia, 2065
- Melanoma Institute Australia
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- One Clinical Research
-
-
-
-
Italy
-
Milan, Italy, Italia
- Divisione di Oncologia Medica del Melanoma
-
Naples, Italy, Italia
- Instituto Nazionale Tumori IRCCS Fondazione
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Be at least 18 years of age on day of signing informed consent.
-
Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system.
- Patient may not have a diagnosis of uveal or ocular melanoma.
- Patients must be treatment naïve to checkpoint inhibitor (CPI) therapy
- Patients must have testing for a BRAF mutation prior to study entry.
Note: Patients with BRAF V600E mutant melanoma may have received prior BRAF inhibitor therapy as first-line systemic therapy and be eligible for this study as second line treatment. At the discretion of the investigator, patients with BRAF V600E mutant melanoma who have NOT received a BRAF inhibitor are also eligible for this study as first line treatment if they meet the following additional criteria:
i. LDH < local ULN, ii. No clinically significant tumor related symptoms in the judgment of the investigator, and iii. Absence of rapidly progressing metastatic melanoma in the judgment of the investigator
- Have measurable disease per RECIST 1.1 as assessed by the local site investigator within 4 weeks prior to the first visit. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- Patients must be willing and able to provide fresh or frozen tumor tissue from an unresectable or metastatic site of disease for neoepitope and biomarker analyses. If a sufficient amount of tumor tissue from an unresectable or metastatic site is not available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue. In addition, participants may provide additional biopsy at the time of discontinuation due to progression.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
- Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
- Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
- Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: EVX-01 in combination with pembrolizumab
EVX-01 is administered im. Pembrolizumab is administered according to label |
Investigational drug given in combination with standard of care Standard of care
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in the best overall response (BOR)
Periodo de tiempo: Measurements at Baseline through study completion (up to 102 weeks)
|
Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria |
Measurements at Baseline through study completion (up to 102 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in overall response rate
Periodo de tiempo: Measurements at Baseline through study completion (up to 102 weeks)
|
Overall response rate, defined as the proportion of the patients who have best response as CR or PR assessed 2 years after initiation of treatment with pembrolizumab, as per RECIST 1.1 criteria |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Change in progression free survival (PFS)
Periodo de tiempo: Measurements at Baseline through study completion (up to 102 weeks)
|
PFS in patients with an assessment of SD, PR, or CR at the time of first EVX-01 administration, assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from the first EVX-01 administration to the first documented disease progression per RECIST 1.1. criteria or death due to any causes, whichever occurs first |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Change in overall survival (OS)
Periodo de tiempo: Measurements at Baseline through study completion (up to 102 weeks)
|
OS assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from initiation of treatment of pembrolizumab to death due to any cause |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs)
Periodo de tiempo: Measurements at Baseline through study completion (up to 102 weeks)
|
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs) |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Immunologic response induced by EVX-01
Periodo de tiempo: Measurements at Baseline through study completion (up to 102 weeks)
|
Activation and level of neoepitope specific T-cells before, during and after EVX-01 immunization |
Measurements at Baseline through study completion (up to 102 weeks)
|
|
Percentage of patients in which EVX-01 is generated, produced, and administered
Periodo de tiempo: From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)
|
Percentage of patients in which EVX-01 is generated, produced, and administered |
From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Enfermedades de la piel
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Tumores neuroendocrinos
- Nevos y Melanomas
- Neoplasias De La Piel
- Enfermedades de la piel y del tejido conectivo
- Melanoma
- pembrolizumab
Otros números de identificación del estudio
- EVX-01-001
- KEYNOTE-D36 (Otro identificador: Merck Sharp & Dohme Corp.)
- 2024-512393-10-00 (Ctis)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .